Category Arguments from Pharma

FDA has low efficacy threshold for approving cancer medicines

Drug price increases are common in the USA

Falsified drugs are less of a problem (anti-malarials) than drug quality, which is a regulatory issue

Hedge-fund style Pharmaceutical strategies impact patients the most, but have less impact on health systems and insurance companies than do smaller price increases on widely used drugs.

Examples of enormous price raises of old drugs

Excessive profit margins by Big Pharma rebutted by R&D costs, long-term healthcare savings, and short window to make profit.

Pharma patient assistance programs can act as industry subsidies.

Pharma patient assistance programs do not have enough data to support them.

CPTech’s (KEI) summary of pharma-favoured academics

COUNTERING: “only 1-4% of essential medicines are patented”